Novo Nordisk (NVO.US) signs contract with Ypsomed for the production of the next-generation weight loss drug pen

Market IntelFriday, Nov 22, 2024 9:30 am ET

1min read

Intellidex learned that insiders revealed that Novo Nordisk (NVO.US) has contracted with Swiss medical device manufacturer Ypsomed to provide pens for its next-generation obesity treatment drug CagriSema. The report showed the company's long-term commercial plan for a weekly injection, which is currently in late-stage clinical development and is expected to generate 3rd phase data this year.

CagriSema is designed to combine semaglutide and another compound that simulates the metabolic hormone amylin. Semaglutide is the active ingredient in Novo Nordisk's popular weight loss therapy Wegovy. Novo Nordisk hopes to achieve an average weight loss of 25% within a year, compared with 15% and 20% for its competitors Eli Lilly (LLY.US) developed weight loss therapy Zepbound.

Last year, Ypsomed signed a long-term agreement to provide Novo Nordisk with auto-injectors aimed at self-administration of treatments for various metabolic diseases.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.